About RXi Pharmaceuticals (NASDAQ:RXII)
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye. The company also develops Samcyprone, a topical formulation of the small molecule diphenylcyclopropenone that is in a Phase IIa clinical trial for the clearance of common warts; RXI-231, an sd-rxRNA compound targeting tyrosinase, as a cosmetic ingredient that may enhance the appearance of uneven skin tone and pigmentation; and RXI-185, an sd-rxRNA compound targeting collagenase, as a cosmetic ingredient that may improve the appearance of wrinkles or skin laxity. In addition, it develops RXI-109, a Phase I/II clinical trial that reduces the progression of retinal scarring. RXi Pharmaceuticals Corporation has collaborations with Center for Cancer Immune Therapy; Gustave Roussy; Medigene AG; and PCI Biotech. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RXII
CUSIPN/A
Phone508-767-3861
Debt
Debt-to-Equity RatioN/A
Current Ratio1.69%
Quick Ratio1.69%
Price-To-Earnings
Trailing P/E Ratio-0.65
Forward P/E Ratio-0.80
P/E GrowthN/A
Sales & Book Value
Annual Sales$10,000.00
Price / Sales1,167.24
Cash FlowN/A
Price / CashN/A
Book Value$0.77 per share
Price / Book3.56
Profitability
EPS (Most Recent Fiscal Year)($4.20)
Net Income$-12,450,000.00
Net MarginsN/A
Return on Equity-194.79%
Return on Assets-130.42%
Miscellaneous
Employees15
Outstanding Shares4,260,000
RXi Pharmaceuticals (NASDAQ:RXII) Frequently Asked Questions
What is RXi Pharmaceuticals' stock symbol?
RXi Pharmaceuticals trades on the NASDAQ under the ticker symbol "RXII."
When did RXi Pharmaceuticals' stock split? How did RXi Pharmaceuticals' stock split work?
RXi Pharmaceuticals shares reverse split on Monday, January 8th 2018. The 1-10 reverse split was announced on Friday, January 5th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 5th 2018. An investor that had 100 shares of RXi Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.
How were RXi Pharmaceuticals' earnings last quarter?
RXi Pharmaceuticals (NASDAQ:RXII) issued its quarterly earnings results on Monday, March, 26th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.96) by $0.12. The biotechnology company had revenue of $0.02 million for the quarter. During the same quarter last year, the company earned ($6.02) earnings per share. View RXi Pharmaceuticals' Earnings History.
When is RXi Pharmaceuticals' next earnings date?
Who are some of RXi Pharmaceuticals' key competitors?
Some companies that are related to RXi Pharmaceuticals include Imprimis Pharmaceuticals (IMMY), Avenue Therapeutics (ATXI), Novus Therapeutics (NVUS), Sernova (SEOVF), AzurRx BioPharma (AZRX), IntelGenx Technologies (IGXT), Vivus (VVUS), Celsion (CLSN), Capricor Therapeutics (CAPR), Evoke Pharma (EVOK), PLx Pharma (PLXP), Chiasma (CHMA), Edge Therapeutics (EDGE), Lipocine (LPCN) and Nemus Bioscience (NMUS).
Who are RXi Pharmaceuticals' key executives?
RXi Pharmaceuticals' management team includes the folowing people:
- Dr. Geert Cauwenbergh Ph.D., Dr., Med.Sc., Pres, CEO, Acting CFO & Director (Age 64)
- Ms. Caitlin Kontulis, Director of Fin., Principal Accounting Officer, Sec. & Controller (Age 32)
- Dr. Karen Bulock Ph.D., VP of Research
- Dr. Gerrit Dispersyn Dr. Med. Sc, Chief Devel. Officer (Age 43)
Has RXi Pharmaceuticals been receiving favorable news coverage?
News stories about RXII stock have trended somewhat positive this week, according to Accern Sentiment. The research group scores the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. RXi Pharmaceuticals earned a media sentiment score of 0.24 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 45.04 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are RXi Pharmaceuticals' major shareholders?
RXi Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include
EQUILIBRIA CAPITAL MANAGEMENT LTD
(48.20%) and
EQUILIBRIA CAPITAL MANAGEMENT LTD
(48.20%). Company insiders that own RXi Pharmaceuticals stock include Alexey Eliseev, Geert Cauwenbergh and Gerrit Dispersyn. View Institutional Ownership Trends for RXi Pharmaceuticals.
How do I buy shares of RXi Pharmaceuticals?
Shares of RXII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is RXi Pharmaceuticals' stock price today?
One share of RXII stock can currently be purchased for approximately $2.74.
How big of a company is RXi Pharmaceuticals?
RXi Pharmaceuticals has a market capitalization of $11.74 million and generates $10,000.00 in revenue each year. The biotechnology company earns $-12,450,000.00 in net income (profit) each year or ($4.20) on an earnings per share basis. RXi Pharmaceuticals employs 15 workers across the globe.
How can I contact RXi Pharmaceuticals?
RXi Pharmaceuticals' mailing address is 257 SIMARANO DRIVE SUITE 101, MARLBOROUGH MA, 01752. The biotechnology company can be reached via phone at 508-767-3861 or via email at [email protected]
MarketBeat Community Rating for RXi Pharmaceuticals (RXII)
MarketBeat's community ratings are surveys of what our community members think about RXi Pharmaceuticals and other stocks. Vote "Outperform" if you believe RXII will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RXII will underperform the S&P 500 over the long term. You may vote once every thirty days.
RXi Pharmaceuticals (NASDAQ:RXII) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | N/A | N/A | N/A | N/A |
| Consensus Rating Score: | N/A | N/A | N/A | N/A |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | N/A | N/A | N/A | $17.10 |
| Price Target Upside: | N/A | N/A | N/A | 6.87% upside |
RXi Pharmaceuticals (NASDAQ:RXII) Consensus Price Target History
RXi Pharmaceuticals (NASDAQ:RXII) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 11/21/2016 | S&P Equity Research | Lower Price Target | | $23.50 -> $17.10 | N/A |  |
| 6/7/2016 | HC Wainwright | Initiated Coverage | Buy | $35.00 | N/A | |
(Data available from 4/24/2016 forward)
RXi Pharmaceuticals (NASDAQ:RXII) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
RXi Pharmaceuticals (NASDAQ RXII) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.71%
Institutional Ownership Percentage: 8.63%
RXi Pharmaceuticals (NASDAQ RXII) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 10/2/2017 | Geert Cauwenbergh | CEO | Buy | 10,000 | $0.45 | $4,500.00 | 135,283 | |
| 9/7/2017 | Alexey Eliseev | Insider | Sell | 176,800 | $0.54 | $95,472.00 | 1,100,931 | |
| 9/1/2017 | Alexey Eliseev | Insider | Sell | 23,200 | $0.57 | $13,224.00 | 1,127,112 | |
| 8/24/2017 | Geert Cauwenbergh | CEO | Buy | 10,000 | $0.55 | $5,500.00 | 127,483 | |
| 6/23/2017 | Gerrit Dispersyn | Insider | Buy | 3,500 | $0.62 | $2,170.00 | 3,500 | |
| 6/22/2017 | Geert Cauwenbergh | CEO | Buy | 10,000 | $0.63 | $6,300.00 | 117,583 | |
| 4/26/2017 | Geert Cauwenbergh | CEO | Buy | 10,000 | $0.65 | $6,500.00 | 112,583 | |
| 3/17/2017 | Geert Cauwenbergh | CEO | Buy | 10,000 | $0.77 | $7,700.00 | 101,903 | |
| 2/17/2017 | Geert Cauwenbergh | CEO | Buy | 10,000 | $0.69 | $6,900.00 | 82,783 | |
| 2/8/2017 | Geert Cauwenbergh | CEO | Buy | 10,000 | $0.69 | $6,900.00 | 82,583 | |
| 1/25/2017 | Geert Cauwenbergh | CEO | Buy | 10,000 | $0.70 | $7,000.00 | 62,883 | |
| 1/19/2017 | Geert Cauwenbergh | CEO | Buy | 10,000 | $0.69 | $6,900.00 | 58,983 | |
| 4/2/2015 | Geert Cauwenbergh | CEO | Buy | 5,000 | $0.72 | $3,600.00 | | |
| 2/17/2015 | Geert Cauwenbergh | CEO | Buy | 4,000 | $1.17 | $4,680.00 | | |
| 2/10/2015 | Geert Cauwenbergh | CEO | Buy | 2,000 | $1.24 | $2,480.00 | | |
| 1/22/2015 | Robert J Bitterman | Director | Buy | 5,000 | $1.20 | $6,000.00 | | |
| 1/20/2015 | Geert Cauwenbergh | CEO | Buy | 10,000 | $1.03 | $10,300.00 | | |
| 12/30/2014 | Geert Cauwenbergh | CEO | Buy | 2,500 | $1.59 | $3,975.00 | | |
| 10/13/2014 | Geert Cauwenbergh | CEO | Buy | 3,000 | $1.68 | $5,040.00 | | |
| 9/19/2014 | Geert Cauwenbergh | CEO | Buy | 4,500 | $2.20 | $9,900.00 | | |
| 9/16/2014 | Geert Cauwenbergh | CEO | Buy | 5,000 | $2.08 | $10,400.00 | | |
| 9/15/2014 | Geert Cauwenbergh | CEO | Buy | 10,000 | $2.18 | $21,800.00 | | |
| 7/15/2014 | Geert Cauwenbergh | CEO | Buy | 1,000 | $2.50 | $2,500.00 | | |
| 7/9/2014 | Geert Cauwenbergh | CEO | Buy | 1,400 | $2.57 | $3,598.00 | | |
| 7/2/2014 | Geert Cauwenbergh | CEO | Buy | 2,000 | $2.86 | $5,720.00 | | |
| 6/19/2014 | Geert Cauwenbergh | CEO | Buy | 2,000 | $2.98 | $5,960.00 | | |
| 6/9/2014 | Geert Cauwenbergh | CEO | Buy | 1,000 | $3.05 | $3,050.00 | | |
| 6/4/2014 | Geert Cauwenbergh | CEO | Buy | 2,000 | $2.94 | $5,880.00 | | |
| 10/31/2013 | Geert Cauwenbergh | CEO | Buy | 1,000 | $3.17 | $3,170.00 | | |
| 10/23/2013 | Geert Cauwenbergh | CEO | Buy | 1,000 | $3.34 | $3,340.00 | | |
| 10/9/2013 | Geert Cauwenbergh | CEO | Buy | 1,000 | $3.15 | $3,150.00 | | |
| 8/29/2013 | Curtis Lockshin | Director | Buy | 1,000 | $3.70 | $3,700.00 | | |
(Data available from 1/1/2013 forward)
RXi Pharmaceuticals (NASDAQ RXII) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Norway's PCI Biotech sees promising data ahead of key study -CEO
finance.yahoo.com - April 24 at 9:05 AM |
| RXi Pharmaceuticals to Webcast First Quarter 2018 Financial Results on Thursday, May 10, 2018
finance.yahoo.com - April 24 at 9:05 AM |
 | BRIEF-Intracoastal Capital LLC Reports 9.2 Pct Passive Stake In RXI Pharmaceuticals Corp, As Of April 9
www.reuters.com - April 19 at 9:06 AM |
 | RXi Pharmaceuticals Announces Publication in Molecular Therapy on Self-Delivering RNAi (sd-rxRNA®) Targeting PD ...
www.prnewswire.com - April 17 at 5:09 PM |
| RXi Pharmaceuticals Announces Publication in Molecular Therapy on Self-Delivering RNAi (sd-rxRNA®) Targeting PD-1 in Adoptive Cell Therapy for the Treatment of Malignant Melanoma
finance.yahoo.com - April 16 at 4:40 PM |
| RXi Pharmaceuticals Announces Closing of $4.9 Million Registered Direct Offering
finance.yahoo.com - April 11 at 4:45 PM |
 | RXI Pharma (RXII) Reports $4.9 Million Registered Direct Offering Priced At-the-Market (Earlier)
www.streetinsider.com - April 10 at 9:32 AM |
| RXi Pharmaceuticals Announces $4.9 Million Registered Direct Offering Priced At-the-Market
finance.yahoo.com - April 9 at 4:40 PM |
 | RXi Pharma on deck for presentations at dermatology conference; shares up 31%
seekingalpha.com - April 4 at 4:45 PM |
| RXII: TIL Program Moving Forward while Waiting on Partnerships
finance.yahoo.com - April 4 at 4:45 PM |
 | 30 Stocks Moving In Wednesday's Mid-Day Session
feeds.benzinga.com - April 4 at 2:16 PM |
| RXi Pharmaceuticals to Present an Update on its Clinical and Cosmetic Dermatology Programs at the International Investigative Dermatology Conference
www.prnewswire.com - April 4 at 7:34 AM |
 | RXi Pharmaceuticals (RXII) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - April 3 at 12:30 AM |
| RXi Pharmaceuticals (RXII) Presents At Landmark Venture Forum 2018 - Slideshow
seekingalpha.com - March 28 at 4:40 PM |
| Edited Transcript of RXII earnings conference call or presentation 26-Mar-18 9:00pm GMT
finance.yahoo.com - March 27 at 4:37 PM |
| RXI Pharma (RXII) Reports Q4 Loss of $0.84/Share
www.streetinsider.com - March 27 at 9:33 AM |
| RXi Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Recent Corporate Highlights
finance.yahoo.com - March 27 at 9:33 AM |
| RXi Pharmaceuticals beats by $0.12
seekingalpha.com - March 26 at 4:52 PM |
| RXi Pharmaceuticals Discusses the Immuno-Oncology Space and Target Indications in New SNNLive Video Interview with StockNewsNow.com
finance.yahoo.com - March 22 at 9:22 AM |
| RXi Pharmaceuticals to Webcast Fourth Quarter and Year End 2017 Financial Results on Monday, March 26, 2018
www.prnewswire.com - March 21 at 1:24 PM |
| RXi Pharmaceuticals (RXII) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - March 21 at 1:18 AM |
| RXi Pharmaceuticals Selected to Present at the Landmark Venture ... - PR Newswire (press release)
www.prnewswire.com - March 20 at 4:36 PM |
| RXi Pharmaceuticals Selected to Present at the Landmark Venture Forum
finance.yahoo.com - March 20 at 9:21 AM |
| RXi Pharma adds to rally, up 31% - Seeking Alpha
seekingalpha.com - March 16 at 9:22 AM |
| RXi Pharmaceuticals (RXII) Cut to "Strong Sell" at ValuEngine
www.americanbankingnews.com - March 16 at 12:16 AM |
| Focused on Speculative Trading: RXII, BB, CASA
finance.yahoo.com - March 15 at 5:16 PM |
| Today’s Research Reports on Trending Tickers: Novavax and RXi Pharmaceuticals
finance.yahoo.com - March 15 at 9:01 AM |
| RXi Pharmaceuticals Corp (RXII) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - March 15 at 1:27 AM |
| Global Hypertrophic Scars Therapeutics Pipeline Analysis 2017 by Phase, Molecule Type, Route of Administration and Company
www.prnewswire.com - March 8 at 5:43 PM |
| RXi Pharmaceuticals Corporation (NASDAQ:RXII): Does The -60.33% Earnings Decline Make It An Underperformer?
finance.yahoo.com - March 8 at 5:43 PM |
| Head to Head Comparison: EXACT Sciences (EXAS) vs. RXi Pharmaceuticals (RXII)
www.americanbankingnews.com - March 4 at 11:06 PM |
| RXII: Exploiting a Natural Mechanism: RXi’s sd-rxRNA
finance.yahoo.com - March 2 at 5:22 PM |
| RXi Pharmaceuticals Corp (RXII) Forecasted to Post FY2017 Earnings of ($5.79) Per Share
www.americanbankingnews.com - March 1 at 7:20 AM |
| Financial Survey: RXi Pharmaceuticals (RXII) & Sunesis Pharmaceuticals (SNSS)
www.americanbankingnews.com - February 21 at 7:36 AM |
| Fibrocell Science (FCSC) versus RXi Pharmaceuticals (RXII) Financial Review
www.americanbankingnews.com - February 14 at 7:18 PM |
| RXi Pharmaceuticals to Present at the BIO CEO and Investor Conference
finance.yahoo.com - February 5 at 9:19 AM |
| RXI Pharma (RXII) Says it Regained Compliance with NASDAQ Listing Requirements
www.streetinsider.com - January 25 at 9:22 AM |
| RXi Pharmaceuticals Regains Compliance with NASDAQ Listing Requirements
www.prnewswire.com - January 24 at 12:25 PM |
| RXi Pharmaceuticals to Present at Immuno-Oncology Frontiers World Conference
www.prnewswire.com - January 17 at 7:25 AM |
 | RXi Pharma Outlines 2018 Business Strategy
www.nasdaq.com - January 16 at 3:19 PM |
| RXi Pharmaceuticals Announces Business Strategy to Focus on Immuno-Oncology Programs to Accelerate Growth
finance.yahoo.com - January 16 at 3:19 PM |
| Blog Exposure - RXi Pharma to Execute Reverse Stock Split
finance.yahoo.com - January 9 at 3:19 PM |
| RXI Pharma (RXII) Reports 1-for-10 Reverse Share Split - StreetInsider.com
www.streetinsider.com - January 6 at 3:19 PM |
| RXI Pharma (RXII) Reports 1-for-10 Reverse Share Split
www.streetinsider.com - January 5 at 3:21 PM |
| RXi Pharmaceuticals Announces Reverse Stock Split
finance.yahoo.com - January 5 at 3:21 PM |
| Streetwise Reports Examines How 'Exciting' Collaborations Possible for Biotech's 'Flexible' Platform
finance.yahoo.com - December 21 at 3:19 PM |
| RXI Pharma (RXII) Reports Positive Results from Phase 2 Trial with RXI-109 for Dermal Scarring - StreetInsider.com
www.streetinsider.com - December 19 at 6:50 AM |
 | Rxi Pharma: Phase 2 Trial With RXI-109 Meets Primary Effectiveness Objective
www.rttnews.com - December 18 at 3:19 PM |
| RXI Pharma (RXII) Enters Pact with Medigene to Further Sharpen its Therapeutic T cells - StreetInsider.com
www.streetinsider.com - December 12 at 6:40 AM |
| RXII: sd-rxRNA: A Flexible Platform for Oncology
finance.yahoo.com - December 7 at 3:20 PM |
RXi Pharmaceuticals (NASDAQ:RXII) SEC Filings
This page is loading this company's SEC Filings. Please wait...
RXi Pharmaceuticals (NASDAQ:RXII) Income Statement, Balance Sheet and Cash Flow Statement
RXi Pharmaceuticals (NASDAQ RXII) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
